Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection

Journal of Neuroinflammation

Volumn 11, Issue 1, 2014, Pages

  Suh, Joome ^a   Sinclair, Elizabeth ^b   Peterson, Julia ^b   Lee, Evelyn ^b   Kyriakides, Tassos C ^c   Li, Fang yong ^c   Hagberg, Lars ^d   Fuchs, Dietmar ^e   Price, Richard W ^b   Gisslen, Magnus ^d   Spudich, Serena ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE UNIVERSITY   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Activated T cells; Central Nervous System Viral Infections; HIV; Immune Activation; Inflammation; Neopterin

Indexed keywords

CD38 ANTIGEN; HLA DR ANTIGEN; NEOPTERIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONGITUDINAL STUDY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM INFLAMMATION; PHLEBOTOMY; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; T LYMPHOCYTE ACTIVATION; VIRUS TRANSMISSION; ACTIVE IMMUNIZATION; BLOOD; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INFLAMMATION; METABOLISM; MIDDLE AGED; VIRUS LOAD;

ADULT; BIOMARKERS; CENTRAL NERVOUS SYSTEM; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, ACTIVE; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPTERIN; VIRAL LOAD;

EID: 84924859316     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-014-0199-y     Document Type: Article

References (39)

1. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I: HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER Study. Neurology 2010, 75:2087-2096.
2. Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, Thrasher D, Goetz MB, Stefaniak M: Medication adherence among HIV+adults: effects of cognitive dysfunction and regimen complexity. Neurology 2002, 59:1944-1950.
3. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, McCutchan JA, Reicks C, Grant I: The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004, 10:317-331.
4. Ellis RJ, Deutsch R, Heaton RK, Marcotte TD, McCutchan JA, Nelson JA, Abramson I, Thal LJ, Atkinson JH, Wallace MR, Grant I: Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 1997, 54:416-424.
5. Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinori A, Narciso P: Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007, 45:174-182.
6. Cysique LA, Maruff P, Brew BJ: Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006, 66:1447-1450.
7. Gonzalez-Scarano F, Martin-Garcia J: The neuropathogenesis of AIDS. Nat Rev Immunol 2005, 5:69-81.
8. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M: Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 2002, 16:2145-2149.
9. Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M: Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 47:168-173.
10. Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M: Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 2007, 196:1779-1783.
11. Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, Suttichom D, Suwanwela NC, Jagodzinski L, Michael N, Spudich S, van Griensven F, de Souza M, Kim J, Ananworanich J: Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 2012, 206:275-282.
12. Resnick L, Berger JR, Shapshak P, Tourtellotte WW: Early penetration of the blood-brain-barrier by HIV. Neurology 1988, 38:9-14.
13. Peluso MJ, Meyerhoff DJ, Price RW, Peterson J, Lee E, Young AC, Walter R, Fuchs D, Brew BJ, Cinque P, Robertson K, Hagberg L, Zetterberg H, Gisslen M, Spudich S: Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis 2013, 207:1703-1712.
14. Ragin A, Wu Y, Du H, Ochs R, Epstein L: Injury to the Brain is Evident Early in HIV Infection. In 18th Conference on Retroviruses and Opportunistic Infections (CROI). February 27-March 2, 2011. Boston. Abstract 55LB.
15. Lentz MR, Kim WK, Lee V, Bazner S, Halpern EF, Venna N, Williams K, Rosenberg ES, Gonzalez RG: Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection. Neurology 2009, 72:1465-1472.
16. Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, Fuchs D, Tambussi G, Cinque P, Hecht FM, Price RW: Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis 2011, 204:753-760.
17. Zetola NM, Pilcher CD: Diagnosis and management of acute HIV infection. Infect Dis Clin North Am 2007, 21:19-48.
18. Lindback S, Thorstensson R, Karlsson AC, von Sydow M, Flamholc L, Blaxhult A, Sonnerborg A, Biberfeld G, Gaines H: Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS 2000, 14:2333-2339.
19. Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, Parkin NT, Petropoulos CJ, Richman DD: Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008, 82:5510-5518.
20. Sinclair E, Ronquillo R, Lollo N, Deeks SG, Hunt P, Yiannoutsos CT, Spudich S, Price RW: Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr 2008, 47:544-552.
21. Dahl V, Lee E, Peterson J, Spudich SS, Leppla I, Sinclair E, Fuchs D, Palmer S, Price RW: Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis 2011, 204:1936-1945.
22. Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, Price RW, Fuchs D: Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 2010, 7:15.
23. Werner ER, Bichler A, Daxenbichler G, Fuchs D, Fuith LC, Hausen A, Hetzel H, Reibnegger G, Wachter H: Determination of neopterin in serum and urine. Clin Chem 1987, 33:62-66.
24. Bogner JR, Jungehulsing B, Kronawitter U, Sadri I, Matuschke A, Goebel FD: Expansion of neopterin and beta-2-microglobulin in cerebrospinal-fluid reaches maximum levels early and late in the course of human-immunodeficiency-virus Infection. Clin Investig 1992, 70:665-669.
25. Price RW, Epstein LG, Becker JT, Cinque P, Gisslen M, Pulliam L, McArthur JC: Biomarkers of HIV-1 CNS infection and injury. Neurology 2007, 69:1781-1788.
26. Gisslen M, Chiodi F, Fuchs D, Norkrans G, Svennerholm B, Wachter H, Hagberg L: Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study. Scand J Infect Dis 1994, 26:523-533.
27. Gisslen M, Hagberg L, Fuchs D, Norkrans G, Svennerholm B: Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment - A longitudinal study. J Acquir Immune Defic Syndr 1998, 17:291-295.
28. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvaez AB, Hunt P, Martin JN, Kahn JO, Levy J, McGrath MS, Hecht FM: Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004, 104:942-947.
29. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, Shih R, Lewis J, Wiley DJ, Phair JP, Wolinsky SM, Detels R: Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999, 179:859-870.
30. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R: Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993, 6:904-912.
31. Marcondes MC, Burudi EM, Huitron-Resendiz S, Sanchez-Alavez M, Watry D, Zandonatti M, Henriksen SJ, Fox HS: Highly activated CD8 (+) T cells in the brain correlate with early central nervous system dysfunction in simian immunodeficiency virus infection. J Immunol 2001, 167:5429-5438.
32. Pan X, Baldauf HM, Keppler OT, Fackler OT: Restrictions to HIV-1 replication in resting CD4+ T lymphocytes. Cell Res 2013, 23:876-885.
33. Dolei A, Biolchini A, Serra C, Curreli S, Gomes E, Dianzani F: Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1alpha, MIP-1beta and RANTES beta-chemokines. AIDS 1998, 12:183-190.
34. Spudich S, Gonzalez-Scarano F: HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med 2012, 2:a007120.
35. Benito JM, Lopez M, Lozano S, Martinez P, Gonzalez-Lahoz J, Soriano V: CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses 2004, 20:227-233.
36. Gisslen M, Hagberg L: Antiretroviral treatment of central nervous system HIV-1 infection: a review. HIV Med 2001, 2:97-104.
37. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW: Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis 2006, 194:1686-1696.
38. Neuenburg JK, Cho TA, Nilsson A, Bredt BM, Hebert SJ, Grant RM, Price RW: T-cell activation and memory phenotypes in cerebrospinal fluid during HIV infection. J Acquir Immune Defic Syndr 2005, 39:16-22.
39. Yilmaz A, Yiannoutsos CT, Fuchs D, Price RW, Crozier K, Hagberg L, Spudich S, Gisslen M: Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation 2013, 10:62.